United States trademark law

Lakewood-Amedex Receives Notice of Allowance for Two U.S. Patents Covering the Broad-Spectrum Antimicrobial Nu-8 Bisphosphocin®

Retrieved on: 
Wednesday, May 27, 2020
Intellectual property law, Patent law, United States patent law, Intellectual property organizations, United States Patent and Trademark Office, United States trademark law, Patent

The "Notice of Allowance" indicates that the USPTO is satisfied that the patent applications meet all USPTO requirements.

Key Points: 
  • The "Notice of Allowance" indicates that the USPTO is satisfied that the patent applications meet all USPTO requirements.
  • Steve Parkinson, President and CEO of Lakewood-Amedex, commented, "Allowance of the broad Nu-8 compound patent application is an important development for us.
  • An earlier animal model demonstrated that a single one-hour inhaled Bisphosphocin treatment was enough to eradicate a severe Pseudomonas aeruginosa lung infection.
  • The Company's products and technology are covered by an extensive patent portfolio consisting of granted and/or issued patents and pending patent applications covering many major pharmaceutical markets.

Cemtrex Granted First Patent for Its Revolutionary SmartDesk

Retrieved on: 
Monday, May 18, 2020
Intellectual property law, International Searching and Preliminary Examining Authorities, Patent offices, United States Patent and Trademark Office, United States trademark law, Patent law, Patent

The Company had developed this unique and unparalleled SmartDesk through its own internal research and development and limited resources over a period of eighteen months.

Key Points: 
  • The Company had developed this unique and unparalleled SmartDesk through its own internal research and development and limited resources over a period of eighteen months.
  • This patent (patent no: D883,277S) is the first patent granted to Cemtrex in its history and the first of 18 patents submitted to the USPTO.
  • A blend of futuristic hardware and groundbreaking productivity software, the SmartDesk delivers an efficient user experience in a luxurious package.
  • Cemtrex's CEO, Saagar Govil, commented, "We are extremely delighted that the US Patent Office has recognized that SmartDesk represents a unique, unparalleled and cutting-edge technology by granting the Company this patent.

ThoughtSphere Awarded Patent for Clinical Trial Data Management Breakthrough

Retrieved on: 
Thursday, May 7, 2020
Intellectual property law, United States Patent and Trademark Office, United States trademark law

SANTA CLARA, Calif., May 7, 2020 /PRNewswire/ --ThoughtSphere, a leading cloud-based clinical data hub and analytics provider, has received a patent for its unique approach to tackling clinical trial data overload.

Key Points: 
  • SANTA CLARA, Calif., May 7, 2020 /PRNewswire/ --ThoughtSphere, a leading cloud-based clinical data hub and analytics provider, has received a patent for its unique approach to tackling clinical trial data overload.
  • The U.S. Patent and Trademark Office (USPTO) awarded ThoughtSphere US Patent No.
  • 10,642,854 for its data management environment which adapts to whatever data structure it is ingesting allowing end users to convert these data to a standardized format.
  • ThoughtSphere is a leading cloud-based clinical data hub and analytics company.

GBT Intellectual Properties - Update: Granted Patent, Filing a New Patent and Continuation on Existing Patent Filed

Retrieved on: 
Thursday, May 7, 2020
Intellectual property law, Patent law, United States patent law, Patent offices, United States Patent and Trademark Office, United States trademark law, Provisional application, Patent application, Term of patent, Priority right, Patent

GBT has been granted continuation patent for tracking devices, systems and method using patch packages with embedded electronic circuits (US patent number: US 10,616,715 B2) on April 7, 2020, from the USPTO.

Key Points: 
  • GBT has been granted continuation patent for tracking devices, systems and method using patch packages with embedded electronic circuits (US patent number: US 10,616,715 B2) on April 7, 2020, from the USPTO.
  • The patent term typically is twenty (20) years from the filing date of the priority application.
  • On April 19, 2020, GBT Tokenize Corp. filed a provisional patent with USPTO for proximity circle.
  • GBT has a portfolio of Intellectual Property that, when commercialized, will include smart microchips, mobile and security applications and protocols, and supporting cloud software.

Rockridge Venture Law® Leads Challenge Against Trademark Alleging RFRA and Free Exercise of Religion

Retrieved on: 
Wednesday, April 15, 2020
United States trademark law, Intellectual property law, Trademark Trial and Appeal Board, United States Patent and Trademark Office, Trademark, Rockridge, Religious Freedom Restoration Act, Law by country, INDIANA, Property

CHATANOOGA, Tenn., April 15, 2020 /PRNewswire/ --Rockridge Venture Law is leading a trademark dispute concerning whether allegedly biblical references and symbols can be trademarked.

Key Points: 
  • CHATANOOGA, Tenn., April 15, 2020 /PRNewswire/ --Rockridge Venture Law is leading a trademark dispute concerning whether allegedly biblical references and symbols can be trademarked.
  • [1] Rockridge, as pro bono counsel, alleges this new case has important implications for whether biblical verses, shorthands, or phrases can be monopolized by fashion companies.
  • Rockridge has challenged the validity of the brothers' trademark through a cancellation proceeding now pending before TTAB.
  • Among its arguments, Rockridge invokes the Religious Freedom Restoration Act (RFRA) which precludes federal law in the form of trademark issuance from hindering religious freedom.

Neos Therapeutics Announces Issuance of New U.S. Methods of Use Patent for N-desethyloxybutynin

Retrieved on: 
Thursday, April 9, 2020
Intellectual property law, United States Patent and Trademark Office, United States trademark law, Neos, Pharmaceutical industry

10,610,507, which is directed to methods of treating sialorrhea by administering N-desethyloxybutynin, the active pharmaceutical ingredient in NT0502.

Key Points: 
  • 10,610,507, which is directed to methods of treating sialorrhea by administering N-desethyloxybutynin, the active pharmaceutical ingredient in NT0502.
  • The patent, assigned to Neos Therapeutics, is not expected to expire before November 2032.
  • We are very pleased to have secured this important method of use patent from the USPTO.
  • Neos Therapeutics, Inc.(NASDAQ: NEOS) is a commercial-stage pharmaceutical company utilizing its novel microparticle delivery technology to develop and manufacture central nervous system (CNS)-focused products.

Jacobs Awarded Cybersecurity Support Contract by the United States Patent and Trademark Office

Retrieved on: 
Monday, April 6, 2020
Intellectual property law, Cyberwarfare, Computer network security, Intellectual property organizations, Patent offices, United States Patent and Trademark Office, United States trademark law, Computer security

DALLAS, April 6, 2020 /PRNewswire/ -- Jacobs (NYSE:J) was selected by the United States Patent and Trademark Office (USPTO) to provide agency-wide cybersecurity support services for its 18,000-person workforce.

Key Points: 
  • DALLAS, April 6, 2020 /PRNewswire/ -- Jacobs (NYSE:J) was selected by the United States Patent and Trademark Office (USPTO) to provide agency-wide cybersecurity support services for its 18,000-person workforce.
  • The scope of the three-year, $29 million contract covers all systems within the agency's enterprise IT environment with a focus on managing and improving the organizational performance of cybersecurity at USPTO.
  • Jacobs will provide risk management framework, technical and administrative support, continuous monitoring, vulnerability assessment, threat analytics and security engineering for USPTO's workforce.
  • Additional efforts include recommending industry best practices and identifying process improvement opportunities and innovations with cybersecurity tools, techniques and procedures.

Octo Wins Spot on USPTO Intelligent Automation Innovation Support Services (IAISS) Blanket Purchase Agreement (BPA)

Retrieved on: 
Tuesday, March 31, 2020
Technology, Other Technology, Intellectual property law, United States trademark law, Intellectual property organizations, United States Patent and Trademark Office, Patent and Trademark Office

Octo today announced it has been awarded a spot on the United States Patent and Trademark Office (USPTO) Intelligent Automation Innovation Support Services (IAISS) blanket purchase agreement (BPA).

Key Points: 
  • Octo today announced it has been awarded a spot on the United States Patent and Trademark Office (USPTO) Intelligent Automation Innovation Support Services (IAISS) blanket purchase agreement (BPA).
  • Octo has focused attention on emerging technologies for over a decade, said Octo Executive Vice President Charlie McQuillan.
  • This opportunity allows us to bring the most current research and development to USPTO while continuing to support them with core services weve been providing since 2014.
  • We are excited to build on our current relationship and help move the agency forward through advanced innovation and automation.

IGC Receives New Patent from U.S. Patent Office to Treat Cachexia and Eating Disorders in Humans and Veterinary Animals

Retrieved on: 
Friday, March 27, 2020
Alternative medicine, Health, Veterinary, Mental health, Intellectual property law, Patent law, Intellectual property organizations, International Searching and Preliminary Examining Authorities, Patent offices, United States patent law, United States Patent and Trademark Office, United States trademark law, Patent application, Patent

IGC filed this application for its IGC-504 formulation (#15/751,901) on August 11, 2016.

Key Points: 
  • IGC filed this application for its IGC-504 formulation (#15/751,901) on August 11, 2016.
  • A public copy of the patent is available on the USPTO website.
  • A patent for an invention is the grant of a property right to the inventor, issued by the USPTO.
  • The company is based in Maryland, U.S.A. Our website: www.igcinc.us .Twitter @IGCIR
    View source version on businesswire.com: https://www.businesswire.com/news/home/20200326005803/en/

ProtoKinetix Files for Patent Protection for AAGP® to be Used in Dry Eye Disease

Retrieved on: 
Thursday, March 19, 2020
Health, Clinical trials, Research, Science, Optical, Biotechnology, Intellectual property law, United States patent law, United States Patent and Trademark Office, United States trademark law, Patent application, Patent

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) recently filed for patent protection for new applications of its AAGP molecule.

Key Points: 
  • ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) recently filed for patent protection for new applications of its AAGP molecule.
  • Based on these results the company has filed for patent protection with the United States Patent and Trademark Office (USPTO) for the application of DED.
  • Dry Eye Disease is one of the most common ocular problems with an estimated prevalence of almost 5-million people over the age of fifty in the United States alone.
  • Current therapies for dry eye are palliative with a focus on the replacement of tears to reduce symptoms.